tiative for a very long time, Astle has identified many opportunities provided by the BRI and

some great projects are already successfully being implemented with Chinese partners.

The world’s only medicine treating spinal muscular atrophy (SMA) is entering the Chinese market, it was announced Sunday.

The drug is registered under the name Spinraza in the United States and European Union.

Available in more than 40 countries and regions, Spinraza is expected to bring new

hope for those who living with SMA, a genetic disorder that affects muscle control, in China.

SMA affects between one in 6,000 and one in 10,000 in China, a

nd about 95 percent of the patients die 18 months after birth, doctors said.

ax148.cn